Abstract
Repurposing drugs requires finding novel therapeutic indications compared to the ones for which they were already approved. This is an increasingly utilized strategy for finding novel medicines, one that capitalizes on previous investments while derisking clinical activities. This approach is of interest primarily because we continue to face significant gaps in the drug–target interactions matrix and to accumulate safety and efficacy data during clinical studies. Collecting and making publicly available as much data as possible on the target profile of drugs offer opportunities for drug repurposing, but may limit the commercial applications by patent applications. Certain clinical applications may be more feasible for repurposing than others because of marked differences in side effect tolerance. Other factors that ought to be considered when assessing drug repurposing opportunities include relevance to the disease in question and the intellectual property landscape. These activities go far beyond the identification of new targets for old drugs.
Similar content being viewed by others
References
Oprea TI. Sense and nonsense in drug discovery: a chemical perspective. In: Kruse CG, Timmerman H, editors. Towards drugs of the future. Amsterdam: IOS Press; 2008. p. 29–36.
Schuster D, Laggner C, Langer T. Why drugs fail—a study on side effects in new chemical entities. Curr Pharmaceut Design. 2005;11:3545–59.
Lindsay MA. Target discovery. Nat Rev Drug Discov. 2003;2:831–8.
Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–83.
Zhao S, Li S. Network-based relating pharmacological and genomic spaces for drug target identification. PLoS ONE. 2010;5:e11764.
Service RF. Surviving the blockbuster syndrome. Science. 2004;303:1796–9.
Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006;116:2837–42.
Munos B. Lessons from 60 years of pharmaceutical innovation. Nature Rev Drug Discov. 2009;8:959–68.
Chong CR, Sullivan DJ. New uses for old drugs. Nature. 2006;448:645–6.
Oprea TI, Nielsen SK, Ursu O, Yang JJ, Taboureau O, Mathias SL, et al. Associating drugs, targets, clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inf. 2011;30:100–11.
Oprea TI. Virtual screening in lead discovery: a viewpoint. Molecules. 2002;7:51–62.
Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA. 1994;91:12013–7.
Kurumbail RG, Stevens AM, Gierse JK, Mcdonald JJ, Stegeman RA, Pak JA, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996;384:644–8.
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96:7563–8.
Celebrex® (celecoxib) capsules package information, http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8d52185d-421f-4e34-8db7-f7676db2a226
Merck & Co., Inc. Merck announces voluntary worldwide withdrawal of Vioxx® (press release) Whitehouse Station, NJ; 2004 Sep 30.
Da Silva GMS, Lima LM, Fraga CAM, Sant’Anna CMR, Barreiro EJ. The molecular basis for coxib inhibition of p38α MAP kinase. Bioorg Med Chem Lett. 2005;15:3506–9.
PDSP (Psychoactive Drugs Screening Program) certified data, http://pdsp.med.unc.edu/pdsp.php?knowID=&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=celecoxib&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query
Weber W, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004;47:550–7.
Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness—the Achilles heel of drug-target networks. Nat Biotechnol. 2008;26:983–4.
Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science. 2008;321:263–6.
Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, et al. Predicting new molecular targets for known drugs. Nature. 2009;462:175–81.
Mestres J, Seifert SA, Oprea TI. Linking pharmacology to clinical records: cyclobenzaprine and its possible association with serotonin syndrome. Clin Pharmacol Ther. 2011;90:662–5.
Oprea TI, Bauman JE, Bologa CG, Buranda T, Chigaev A, Edwards BS, et al. Drug repurposing from an academic perspective. Drug Discov Today: Therap Strategies. 2011;8:61–9.
Lin BK, Clyne M, Walsh M, Gomez O, Yu W, Gwinn M, et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am J Epidemiol. 2006;164:1–4.
Yang JO, Hwang S, Oh J, Bhak J, Sohn T-K. An integrated database-pipeline system for studying single nucleotide polymorphisms and diseases. BMC Bioinformatics. 2008;9:S19.
Strachan RT, Ferrara G, Roth BL. Screening the receptorome: an efficient approach for drug discovery and target validation. Drug Discov Today. 2006;11:708–16.
Cases M, Mestres J. A chemogenomic approach to drug discovery: focus on cardiovascular diseases. Drug Discov Today. 2009;14:479–85.
Flachner B, Lörincz Z, Carotti A, Nicolotti O, Kuchipudi P, Remez N, et al. A chemocentric approach to the identification of cancer targets. PLoS ONE. 2012;7:e0035582.
Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–52.
Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409–12.
Wermuth CG. The ‘SOSA’ approach: an alternative to high-throughput screening. Med Chem Res. 2001;10:431–9.
Curley D, Easey A. Drug repurposing and repatenting. Bio-Science Law Review. 2009;10:131–4.
Sanderson K. Big interest in heavy drugs. Nature. 2009;458:269.
Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst. 2009;5:1051–7.
Briansó F, Carrascosa MC, Oprea TI, Mestres J. Cross-pharmacology analysis of G protein-coupled receptors. Curr Top Med Chem. 2011;11:1956–63.
Sleigh SH, Barton CL. Repurposing strategies for therapeutics. Pharm Med. 2010;24:151–9.
Collins FS. Mining for therapeutic gold. Nature Rev Drug Discov. 2011;10:397.
Lipworth WL, Kerridge IH, Day RO. Wrong questions, wrong answers? Are we getting the drugs we need? Clin Pharmacol Ther. 2012;91:367–9.
Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10:712–3.
Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, Bourne PE. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol. 2010;6:e1000976.
Shigemizu D, Hu Z, Hung JH, Huang CL, Wang Y, Delisi C. Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput Biol. 2012;8:e1002347.
Acknowledgments
This work was supported, in part, by NIH grants 5R21GM095952-02 and 5U54MH084690-04 (TIO) and by the Spanish Instituto de Salud Carlos III (JM) through the Drugs4Rare project within the framework of the International Rare Disease Research Consortium.
Author information
Authors and Affiliations
Corresponding author
Additional information
Guest Editor: Xiang-Qun Xie
Rights and permissions
About this article
Cite this article
Oprea, T.I., Mestres, J. Drug Repurposing: Far Beyond New Targets for Old Drugs. AAPS J 14, 759–763 (2012). https://doi.org/10.1208/s12248-012-9390-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-012-9390-1